Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence

被引：0
|
作者：
Caponnetto, S. [1 ]
Gelibter, A. [2 ]
Mosillo, C. [2 ]
Magri, V. [2 ]
Scagnoli, S. [2 ]
Pomati, G. [2 ]
Piesco, G. [2 ]
Verkhovskaya, S. [2 ]
Pisegna, S. [2 ]
Sirgiovanni, G. [2 ]
Napoli, V. [2 ]
Buscicchio, D. [2 ]
Iannantuono, G. M. [2 ]
Marinelli, D. [2 ]
Mammone, G. [2 ]
Pannunzio, S. [2 ]
Nicolo, E. [2 ]
Stefani, A. [2 ]
Astorino, V. [2 ]
Mancini, M. [2 ]
Cortesi, E. [2 ]
机构：
[1] Univ Roma La Sapienza, Oncol Med B, Policlin Umberto I, Rome, Italy
[2] Policlin Umberto 1, Oncol Med B, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D27
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [2] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [3] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [4] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [6] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [7] Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
    Pacheco-Barcia, V.
    France, T.
    Zogopoulos, G.
    Bouganim, N.
    Donnay, O.
    Alcindor, T.
    Mondejar Solis, R.
    Guo, K.
    Martin, E.
    Colomer, R.
    Asselah, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [9] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Jihoon Kang
    Inhwan Hwang
    Changhoon Yoo
    Kyu-pyo Kim
    Jae Ho Jeong
    Heung-Moon Chang
    Sang Soo Lee
    Do Hyun Park
    Tae Jun Song
    Dong Wan Seo
    Sung Koo Lee
    Myung-Hwan Kim
    Seung-Mo Hong
    Sang Hyun Shin
    Dae Wook Hwang
    Ki Byung Song
    Jae Hoon Lee
    Song Cheol Kim
    Baek-Yeol Ryoo
    Investigational New Drugs, 2018, 36 : 732 - 741
  • [10] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Kang, Jihoon
    Hwang, Inhwan
    Yoo, Changhoon
    Kim, Kyu-pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Hong, Seung-Mo
    Shin, Sang Hyun
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 732 - 741
12345